Loading…
← CockpitCompetitor Analysis › 688050.SS Eyebright Medical Technology (Beijing) Co., Ltd. Class AOpen in the cockpit ↗

Eyebright Medical Technology (Beijing) Co., Ltd. Class A688050.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese ophthalmic device maker known for orthokeratology (Ortho-K) contact lenses that slow myopia progression.

≈ A Chinese CooperVision/Paragon for myopia-control lensesMomentum strong 78
Mkt cap
$1.21B
US dollars, full cap
Free float
68%
of shares outstanding
$/day
$25.0M
20-day average traded
Fwd P/E
23.9×
forward earnings
ROIC−WACC
+1.4 pp
WACC 6.5%
Hurdle
-30 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥41.09
1D-2.4%
1W-4.2%
1M-2.0%
3M-5.4%
6M-16.1%
YTD-32.3%
1Y-35.2%
ATR %3.9%
52w lowhigh38.1% off high

What Eyebright Medical Technology (Beijing) does

Chinese ophthalmic device maker known for orthokeratology (Ortho-K) contact lenses that slow myopia progression.

Also sells intraocular lenses, the implants that replace a clouded lens in cataract surgery, to hospitals. Ortho-K lenses are paid for privately by families rather than reimbursed by insurance, and the lenses are replaced as they wear, so sales recur with each child under treatment.

In one line: A Chinese CooperVision/Paragon for myopia-control lenses.

Products and services

  • Orthokeratology (Ortho-K) lenses
  • Soft contact lenses
  • Ophthalmic diagnostic devices

Customers

  • Ophthalmologists/optometry clinics
  • Parents of myopic children

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Ophthalmic myopia-control devices

What could go right

  • Childhood myopia prevalence growth in China

What could go wrong

  • Regulatory scrutiny of pediatric eye devices

Moat: narrow (regulatory licence, brand). Ortho-K device approvals and clinical fitting expertise limit new entrants.

Headquarters: Beijing, China · Employees: 2,331

Named competitors

Eyebright Medical Technology (Beijing) at a glance

Size Eyebright Medical Technology (Beijing) (688050.SS) is a China Health Care company (Medical Specialties) with a market value of $1.21B, the 1830th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥41.09 on 18 Nov 2026.

Performance Over six months the shares fell 16.1%, against -9.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 21.1% over the last twelve months (peer median +12.0%); the operating margin is 16.0% (peer median 11.6%).

Valuation It trades at 23.9× forward earnings against a peer median of 32.9× (6th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -30 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.4 points above its cost of capital (6.5% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 88688050.SS 86
Six months, rebased to 100: Eyebright Medical Technology (Beijing) against the median of its 20 peers (local-currency closes).

Eyebright Medical Technology (Beijing) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.79BCN¥1.47BCN¥1.40BCN¥944MCN¥575M
Revenue growth—+5%+49%+64%—
Gross profitCN¥1.20BCN¥875MCN¥871MCN¥677MCN¥460M
EBITDAn/aCN¥533MCN¥574MCN¥395MCN¥284M
Net incomeCN¥244MCN¥268MCN¥388MCN¥304MCN¥233M
Free cash flowCN¥146MCN¥256MCN¥19.3M-CN¥144MCN¥428,190
Capital expenditureCN¥167MCN¥123MCN¥329MCN¥370MCN¥271M
Total debtCN¥1.17BCN¥571MCN¥579MCN¥390MCN¥163M

Quarterly statements and history in the cockpit →

Eyebright Medical Technology (Beijing) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%2675TNDM688289NVCRSTAA688161300406300633688758688198DRTS300595ATEC214150301101688622SIBNIRMD688050.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Eyebright Medical Technology (Beijing) is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×2675688289STAA688161300406300633688758688198300595ATEC214150IART301101688050.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Eyebright Medical Technology (Beijing) is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%STAA688161300406688758688198300595214150IART301101IRMD688050.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Eyebright Medical Technology (Beijing) is the large dot.

Eyebright Medical Technology (Beijing) competitors and peer comparison

Head to head with its named competitors (688050.SS vs COO vs ALC.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Eyebright Medical Technology (Beijing) 688050.SS$1.21B-16%+21%16%23.9×10.3%
Cooper Companies (The) COO$11.6B-2%+5%19%13.4×9.4%
Alcon ALC.SW$36.9B+18%+1%12%21.5×12.2%

How Eyebright Medical Technology (Beijing) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Eyebright Medical Technology (Beijing) against its 20 peers (data as of 18 Nov 2026)
Measure688050.SSPeer medianRank in peer set
1-month return-2.0%-7.5%9th highest of 21
6-month return-16.1%-9.9%9th lowest of 20
Distance from 52-week high-38.1%-37.9%11th highest of 21
Revenue growth (TTM)+21.1%+12.0%4th highest of 19
Operating margin16.0%11.6%10th highest of 20
Forward P/E23.9×32.9×6th cheapest of 15
Growth the price implies (Req g, 7 yrs)10.3%10.0%6th least demanding of 11
Growth delivered (Del g)+40.3%+13.2%highest of 11
Hurdle (Req g minus delivered)-30.0 pp-1.9 pp2nd least demanding of 11
ROIC minus cost of capital+1.4 pp+0.1 pp8th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%16%23.9×10.3%+40.3%
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%120.2×n/an/a
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%35.6×n/an/a
NovoCure NVCRUnited States$1.25B-40%+13%-17%n/an/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%34.7×n/an/a
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%46.0×22.8%+23.6%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%41.5×20.7%+27.6%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Ovctek China 300595.SZChina$1.33B-25%0%28%19.4×8.3%+16.5%
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%

Questions

Who are Eyebright Medical Technology (Beijing)'s main competitors?
Named competitors: CooperVision (CooperCompanies) (COO), Alcon (ALC.SW). The cockpit's measured peer set (industry) also includes Shenzhen Edge Medical (2675.HK), Tandem Diabetes Care (TNDM), Sansure Biotech (688289.SS), NovoCure (NVCR), STAAR Surgical (STAA), Shandong Weigao Orthopaedic Device (688161.SS).
Is Eyebright Medical Technology (Beijing) expensive compared with its peers?
On forward p/e it trades at 23.9× against a peer median of 32.9×, 6th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -30 pp: the price already allows for a slowdown.
How has Eyebright Medical Technology (Beijing) stock performed?
Over six months to 18 Nov 2026 the shares returned -16.1% against -9.9% for the median peer; over one year -35.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.